Updated time: 2021-12-23 15:21:31
28A-1080311
PCT、TW I-749504、
Fluorinated glycosides are known to resist the glycosidase-catalyzed glycosidic bond cleavage; however the synthesis of such glycans, especially 3-fluoro-sialic acid (3F-Neu5Ac) containing sialosides, has been a major challenge. Through the enzymatic synthesis of a 2, 6-linked 3F sialosides was reported, there is no effective method available for the synthesis of 3F-sialosides in the , 6-Linked. In order to understand the biological effect of such modification, we report here a chemical synthesis of 3FaxNeu5Ac-a 2, 6-Gal as building block for the assembly of 3Fax-Neu5Ac-containing sialosides and a representative homogeneous antibody glycoform. Our results showed it can be used as therapeutic agent, the homogeneous antibody can recruit such specific population of immune cells to the target site such as tumor site or infected cell to exhibit the optimal anticancer or anti-infective activity through target killing. It also be used to isolate such immune cells, expand them and the isolated immune cells can be used for cell therapy directly or for further modification such as construction of CAR-NK. In addition, it also be used for imaging the action of antibody in vitro and in vivo if labeled with a probe.
We are the first to have designed a concise and efficient synthetic strategy to generate a rituximab comprising glycoform with a biantennary glycan terminated with 3Fax-Neu5Ac
- Development of therapeutic antibodies or sialosides with improved stability and pharmacokinetic parameters
- Isolation specific immune cells
- Imaging the action of antibody in vitro and in vivo
Chi-Huey Wong、Hong-Jay Lo
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Synthesis of Sialidase-Resistant Oligosaccharide and Antibody Glycoform Containing a 2, 6-Linked 3F-Neu5AC